with specific G1 nab Abs were cleared more slowly from human circulation than IgG1-sensitised counterparts. However, non-destructive splenic retention of G1 nab-coated RBCs required investigation and plasma radioactivities now suggest this also occurred for platelets sensitised with an IgG1/G1 nab mixture. In vitro assays with human cells showed that G1 nab-sensitised RBCs did not cause FcγRI-mediated monocyte activation, FcγRIIIa-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) or macrophage phagocytosis although they did adhere to macrophages. Thus, FcγRII was implicated in the adhesion despite the nab mutation reducing the already low-affinity binding to this receptor class. Additional contacts via P-selectin enhance the interaction of sensitised platelets with monocytes and this system provided evidence of FcγRII-dependent activation by G1 nab. These results emphasise the physiological relevance of low-affinity interactions: It appears that FcγRII interactions of G1 nab allowed splenic retention of G1 nab-coated RBCs with inhibitory FcγRIIb binding preventing RBC destruction and that FcγRIIb engagement by G1 nab on IgG1/G1 nab-sensitised platelets overcame activation by IgG1. Considering therapeutic blocking Abs, G1 nab offers lower FcγR binding and a greater bias towards inhibition than IgG2 and IgG4 constant regions.
Introduction
We have been developing an inert constant region for use in therapeutic Abs with blocking functions. We observed in human volunteers that cells coated with an Ab containing this constant region were unexpectedly sequestered in the spleen. We wished to investigate whether the residual, low-affinity interactions of the Fc might be responsible.
We designed the inert Fc to lack cytotoxic activity but to retain the FcRn binding crucial for long half-life and placental transport. To avoid the creation of new immunogenic epitopes, we incorporated motifs from human IgG2 (residues 233-236) and IgG4 (327, 330 and 331) into an IgG1 constant region [1] . When combined with human anti-RhD variable regions (Fog-1 [2] ), this constant region, G1 ab, showed minimal binding to FcγRI and FcγRIII such that Fog-1 G1 ab-sensitised RBCs did not activate monocytes and were not lysed by NK antibody-dependent cell-mediated cytotoxicity (ADCC). Moreover, Fog-1 G1 ab was able to inhibit the triggering of these activities by either Fog-1 IgG1 wild-type (WT) Ab (Fog-1 G1) or clinical anti-RhD sera [1, 3] . Since binding to the low-affinity FcγRII molecules was also reduced [4] , G1 ab appeared to be a good candidate for an inert constant region and was further modified to G1 nab to eliminate allotypic residues [5] .
In a volunteer study, aliquots of autologous RBCs were labelled with different radionuclides before being coated with either Fog-1 G1 or G1 nab Ab [5] . After re-injection, there was complete, irreversible clearance of G1-coated cells, with accumulation in the spleen and liver and the appearance of radiolabel in plasma. The clearance of cells coated with Fog-1 G1 nab was significantly slower and, surprisingly, was incomplete and transient with blood cell counts rising again after 3-4 h. Scans showed that G1 nab-coated cells accumulated in the spleen but no radiolabel was detected in the plasma. These findings suggest that G1 nab-sensitised cells were not destroyed but showed exaggerated pooling within the spleen. The net increase in circulating, labelled cells at later time points possibly occurred due to elution of G1 nab from the RhD antigen (Ag).
A second G1 nab volunteer study was related to a possible blocking Ab treatment for the condition feto-maternal alloimmune thrombocytopenia, which is due to transplacental passage of maternal anti-human platelet Ag (HPA) Abs, usually anti-HPA-1a. It causes severe fetal thrombocytopenia in 1 in 1200 unselected pregnancies and intrauterine death or intracerebral haemorrhage can result [6] . The current antenatal therapy of high-dose intravenous immunoglobulin is unsatisfactory. An inert HPA-1a-specific Ab could be administered to the mother to cross the placenta and block the interaction of the maternal alloantibodies with HPA-1a on fetal platelets without causing platelet destruction itself. An anti-HPA-1a version of G1 nab was produced with highly specific variable regions (B2 [7, 8] ). B2 G1 nab reduced the monocyte chemiluminescence (CL) response to platelets that were sensitised with B2 IgG1 WT Ab (B2 G1) or with a range of maternal sera containing HPA-1a Abs [9] . The intravascular survival of unsensitised, autologous platelets was compared with the survival of those sensitised with B2 G1, B2 G1 nab or a mixture of the two Abs [10] . Platelets sensitised with G1 (P-G1) were completely cleared from the circulation in 2 h, whilst platelets sensitised with G1 nab (P-G1 nab) showed the same survival as unsensitised platelets (P). Platelets that were sensitised with a combination of B2 G1 and B2 G1 nab (P-G1/G1 nab) were cleared from the circulation similarly to P-G1 but with an improved survival of two-to threefold. We have now analysed the data for the levels of radiolabel appearing in the plasma to see how clearance relates to destruction for each platelet type.
We have investigated the molecular basis for our in vivo observations by assaying Fog-1 and B2 G1 nab in FcγR binding and functional assays. We mimicked the situation in the spleen by looking at the interaction between Fog-1-sensitised RBCs and macrophages. It is difficult to attribute low-affinity interactions of IgGs to particular FcγR in functional assays but it is known that when human monocytes are activated by sensitised platelets, IgG-FcγR interactions are enhanced by additional association through P-selectin [11] . Thus, this was an ideal system for studying low-affinity FcγR binding. Assays were made more informative by including anti-HPA-1a Abs with different FcγR-binding profiles alongside B2 G1 and B2 G1 nab. These were an IgG2 WT molecule (B2 G2) and B2 G1 nac. The G1 nac constant region is identical to G1 nab except that it includes the IgG1 residue G236, which is absent in IgG2 and G1 nab. Previously, G1 ab and G1 ac molecules were shown to be similarly non-destructive overall but to exhibit low levels of activity in different assays [1, 3, 4] . In this way, we hoped to discover which interactions of the G1 nab constant region were relevant to the Abs' behaviour in vivo.
Results

Platelet survival study: Analysis of plasma-associated radioactivity
Each volunteer in the platelet survival study received two samples of autologous, HPA-1a1b platelets that had been left unsensitised or sensitised at saturating concentrations of B2 Ab (0.13 mg/mL) and then labelled with different radionuclides [10] . The previous report focussed on the survival curves generated from the radioactivity in the cellular fractions of the blood samples [10] . Platelet destruction can be inferred from radioactivity appearing in the plasma but only for platelets radiolabelled with 111 In since 51 Cr elutes too rapidly. This limits the number of data sets available for each type of platelet: unsensitised (n = 3), P-G1 (n = 5), P-G1 nab (n = 4) or P-G1/G1 nab (10% B2 G1/90% B2 G1 nab, n = 2). Figure 1 compares the plasma-associated 111 In radioactivity levels measured for the four types of platelets and shows the corresponding platelet survival curves when data are restricted to these platelet samples. The graphs are limited to the first 24 h after injection because B2 Abs redistribute to the whole platelet population by this time point [10] . Large error bars result from donor variation and the small group sizes mean statistics cannot be applied but there was a higher level of plasma 111 In activity associated with P-G1 than for the other types of platelets. The result is particularly striking for P-G1/G1 nab, given that the survival curves for these platelets and P-G1 are similar. In fact, one of the volunteers receiving the 111 In-labelled P-G1/G1 nab had significantly higher HPA-1a levels on their platelets than all other volunteers (UPN 18; see table 1 of [10] ). These P-G1/G1 nab were cleared more quickly than all other samples of P-G1/G1 nab but this was not accompanied by increased levels of 111 In in the plasma. In-labelled samples of unsensitised platelets, P-G1, P-G1 nab and P-G1/G1 nab in three, five, four and two volunteers, respectively. For unsensitised platelets, only data from volunteers who received G1 nab-coated, 51 Cr-labelled platelets alongside are included as, when G1 was present on the other platelets, higher levels of plasma 111 In were seen, presumably due to IgG exchange in the pre-injection mixture. Thus, data are restricted to the 111 In-labelled samples of volunteers 1-7, 9 and 13-18 (detailed in [10] ). The curves for each type of platelet represent the mean ± SD of the activities in the different individuals or, for P-G1/G1 nab, the range of the activities in the two individuals.
Binding of anti-RhD and anti-HPA-1a Abs to FcγR
To investigate the basis for the removal of the G1 nab-sensitised RBCs and platelets from the circulation, we used transfected cell lines, each expressing a single human FcγR, to assess the level of interaction of G1 nab Abs in comparison with the WT IgG1 controls. For the anti-HPA-1a Abs, we also included the WT IgG2 (B2 G2) and the mutant B2 G1 nac. Binding of monomeric IgG to the high affinity FcγRI was measured for the Fog-1 (not shown) and B2 Abs ( Fig. 2A) . G1 bound strongly whereas no binding of G2 or G1 nab was detected at concentrations ≤100 μg/mL. G1 nac showed a small degree of binding at ≥30 μg/mL.
For the lower affinity receptors of the FcγRII and III classes, the binding of pre-complexed IgG was measured so that the avidity effect would allow low levels of interaction to be visualised. For FcγRIIa, of allotypes 131R and 131H, and FcγRIIb, Fog-1 G1 nab bound three-to eightfold less strongly than Fog-1 G1 but substantially more than IgA negative control (not shown and Fig. 2C and D). With the B2 Abs, G1 nab bound more strongly than G1 nac to FcγRIIa, of allotypes 131R (Fig. 2B ) and 131H (not shown). These two mutants showed approximately equal binding to FcγRIIb (not shown). For both Fog-1 and B2 Abs, G1 nab binding to FcγRIIIa was above that of the IgA negative control but was approximately 100-fold (158F allotype) or 50-fold (158V allotype) lower than G1 binding ( Fig. 2E-H ). In the B2 Ab set, G1 nac and G2 both bound more strongly than G1 nab to FcγRIIIa ( Fig. 2G and H). For FcγRIIIb, of NA1 and NA2 allotypes, only Fog-1 G1 or B2 G1 complex binding could be detected at concentrations ≤100 μg/mL (not shown).
Functional assays of responses to Fog-1-sensitised RBCs
Saturation of RBC RhD sites was achieved at coating concentrations of 20 μg/mL and 50% saturation at approximately 0.4 μg/mL for all Fog-1 Abs (not shown). Measurement of NK-cell-mediated ADCC of Fog-1 IgG-sensitised RBCs showed G1 to be highly active at sub-saturating concentrations whilst any lysis caused by G1 nab was at background levels ( Fig. 3A) . Fog-1 G1-sensitised RBCs efficiently activated monocytes, as seen by their CL response, whereas G1 nab-sensitised RBCs did not cause activation even when the RhD sites were saturated with Ab ( Fig. 3B) .
RBCs, whose RhD sites had been saturated with Fog-1 Ab, were incubated with macrophages to assess their ability to interact. The number of G1 nab-coated RBCs associated with the macrophages was significantly greater than for unsensitised cells (p < 0.05, paired Student's t-test) and, for each donor, amounted to approximately 30% of the numbers of associated G1-sensitised cells (Fig. 4) . However, very few G1 nab cells were within the macrophages and the proportion of macrophage-associated G1-sensitised RBCs that had been internalised was significantly larger (p < 0.05, paired Student's t-test). Furthermore, the macrophages incubated with the unsensitised and G1 nabsensitised RBCs retained a contracted morphology whilst those incubated with the G1-coated cells had spread.
Monocyte CL responses to HPA-1a Abs
HPA 1a/1b platelets were used to match the genotype of platelets in the survival study. The four B2 Abs gave identical platelet binding curves, with saturation being approached at 5-10 μg/mL (not shown). The monocyte CL response to P-G1 or platelets sensitised with B2 G2 (P-G2) was dependent on the degree of sensitisation and was maximal at 10 μg/mL Ab (Fig. 5A ). The response to P-G2 was approximately 30% of that to P-G1 at each Ab concentration. CL responses to P-G1 nab and platelets sensitised with G1 nac (P-G1 nac) were similar at 12-13% of P-G1 values (p < 0.0001) across the concentration range but were greater than those observed to the control Ab at concentrations ≥5 μg/mL (p < 0.0001). No CL response was obtained when HPA-1b/1b platelets were used (not shown). When viewed as CL signal against time, the response to P-G1 is characterised by a rapid rise in signal that peaks before 10 min whilst the other B2 Abs cause a slow signal increase that approaches a plateau at 45 min (Fig. 5B) . As the coating concentration of B2 G1 is decreased, the rapid rise in CL signal is lost such that a curve for 1 μg/mL G1 resembles that for 10 μg/mL G2 (not shown). The residual CL response to P-G1 nab or P-G1 nac was not due to the mutated Abs causing platelet activation since the P-selectin expression of platelets sensitised with 100 μg/mL each B2 IgG was not significantly different from platelets incubated with an IgG1 isotype control (MFI 0.7 ± 0.8 units), whereas thrombin-stimulated platelets gave much higher expression (MFI 16.2 ± 1.3 units).
The above experiments measured the response of monocytes to pre-sensitised platelets. A more rapid response was seen when HPA-1a Abs were added to pre-adhered monocytes and platelets. The CL signal peaked before the first time point (not shown) and the calculated CL response was greater in magnitude. Using concentrations of each B2 Ab that elicited sub-maximal CL responses, the increase attributable to pre-adhesion amounted to twofold for 1 μg/mL G1, threefold for 5 μg/mL G2 and seven-to eightfold for 10 μg/mL G1 nab or G1 nac. There was no response to IgG1 isotype control or when using HPA-1b/1b platelets (not shown).
Characterisation of the FcγR involved in the CL responses to HPA-1a Abs
Monocytes were pre-incubated with blocking agents to inhibit IgG binding to FcγRI or FcγRII. When 20 μg/mL monomeric murine IgG 2a Ab was used to block FcγRI, the CL responses to P-G1 and P-G1 nac were reduced by 90% whereas CL responses to P-G1 nab and P-G2 were only reduced by 9 and 18%, respectively (Fig. 5C) .
Fab fragments of the anti-FcγRII mAb IV.3 were used to block binding to FcγRIIa. IV.3 whole antibody staining of FcγR-expressing cell lines has shown it to have 1000-fold greater affinity for FcγRIIa than FcγRIIb (not shown) so use of IV.3 Fab will have resulted in little FcγRIIb blocking. Donors homozygous for the 131R allotype of FcγRIIa, which binds murine IgG 1 , were used to enable demonstration of efficient blocking of FcγRIIa by IV.3 Fab: the CL response to a murine IgG 1 CD41Ab was inhibited by 98%. Responses to P-G2 and P-G1 nab were reduced by more than 80% to control levels whereas responses to P-G1 and P-G1 nac were not inhibited (Fig. 5D) . Indeed, responses to P-G1 tended to be enhanced.
Discussion
Our human volunteer studies have now revealed two instances of non-destructive sequestration that might be explained by lowaffinity IgG-FcγR interactions. Previously, in the RBC survival study, imaging showed that Fog-1 G1 nab-coated cells were retained in the spleen but, since there was no release of radiolabel into the plasma, any interaction with splenic FcγR did not drive their destruction [5] . Now, evaluation of the 111 In activity levels in the plasma fractions from the platelet survival study [10] has shown low activities for unsensitised platelets, P-G1 nab and, remarkably, P-G1/G1 nab whereas higher activities reflected the rapid rate of P-G1 destruction. The shape of the P-G1/G1 nab survival curves had suggested platelet destruction albeit at a slower rate than for G1-coated platelets: the calculated survival of P-G1/G1 nab was 58 ± 12 min against 18 ± 5 min for P-G1 for all data sets [10] . Plasma activity levels suggest that the loss of circulating P-G1/G1 nab was due to sequestration rather than destruction. Thus, the behaviour of these platelets paralleled that of the G1 nab-coated cells in the RBC study and may have been due to prolonged splenic pooling. The proposed G1 nab treatment of thrombocytopenic fetuses should result in all platelets being coated with a mixture of active and inactive IgGs so, assuming a limited capacity for splenic retention, most platelets would remain in circulation.
The interaction between Fog-1-sensitised RBCs and macrophages was investigated in vitro as a model for the interactions between G1 nab Abs and splenic FcγR and produced two important results. Firstly, although the numbers of G1 nab-sensitised RBCs associated with the macrophages were threefold lower than for G1-sensitised RBCs, they were significantly higher than for unsensitised RBCs. This suggests that the interactions of G1 nab with one or more macrophage FcγRs, namely FcγRI, FcγRIIa, FcγRIIb and FcγRIIIa [12] , are strong enough to promote association. G1 nab-sensitised RBCs did not trigger monocyte activation or ADCC and these activities are known to be FcγRI-and FcγRIIIa-mediated, respectively [3, 11] . Thus, it is most likely that G1 nab-sensitised RBCs adhered to macrophages via interactions with FcγRIIa or FcγRIIb. The second observation was that a much lower proportion of macrophageassociated RBCs were internalised for Fog-1 G1 nab compared to Fog-1 G1. Due to inter-donor variation, perhaps resulting from differences in levels of FcγR expression or from receptor polymorphisms, G1 nab-sensitised RBCs associated with donor 1 macrophages to a similar extent as G1-sensitised RBCs with donor 3 macrophages. Even in these circumstances, greater numbers of the G1 cells were internalised. Perhaps G1 nab-sensitised RBCs did not trigger phagocytosis because their interactions with activating FcγR were insufficient to overcome the inhibitory effect of cross-linking FcγRIIb.
The numbers of G1 nab-sensitised RBCs adhering to macrophages were too small to allow easy investigation of the types of FcγR involved. Monocytes also express FcγRI, FcγRIIa, FcγRIIb and, sometimes, FcγRIIIa [12] and their activation by Abcoated platelets is a more sensitive system as it is partially mediated by the interaction between platelet P-selectin and P-selectin glycoprotein ligand-1 on monocytes [11] . This allowed the effects of blocking the different FcγR to be examined but, since B2 G1 nab exhibits only low-affinity FcγR binding, it was important to show that a specific interaction was being blocked. As a control, we used B2 G1 nac, an IgG that also showed only low-affinity FcγR binding but with a distinct receptor profile. In addition to the B2 Ab binding experiments here, FcγR binding of G1 ab and G1 ac constant regions has been compared in the context of Fog-1 and CAMPATH variable regions without the null allotype mutations [1, 3, 4] . The hierarchy of binding to each receptor was retained whatever the setting of the mutations. Binding to FcγRI of ab-containing Abs was at background levels like IgG2 whereas ac mutants retained slight binding at 100 μg/mL. It was with FcγRII receptors that the mutations had the least effect on binding; in particular, binding to the inhibitory receptor, FcγRIIb, was only reduced by three-to fourfold. The hierarchies were G1 > G2 > G1 ab > G1 ac for FcγRIIa of the 131R allotype, G2 ≥ G1 > G1 ab > G1 ac for FcγRIIa 131H and G1 > G2 > G1 ab ≈ G1 ac for FcγRIIb. For FcγRIIIa, the order was G1 >> G1 ac > G2 > G1 ab whereas, of these Abs, only G1 showed measurable binding to FcγRIIIb. The G1 nab and G1 nac constant regions differ only by the absence or presence of G236. It has been suggested that the flexibility given by G236 and G237, as in the IgG1 lower hinge, is required for binding to FcγRI and FcγRIII due to the tightness of the fit but that the equivalent contact residues of FcγRII are smaller and allow binding of the IgG2 lower hinge without G236 [13] . This might explain the binding preferences of G1 nab and G1 nac.
The tethering via P-selectin allowed P-G1 nab and P-G2 to activate monocytes at 12-13% and 30% of the P-G1 level whereas G1 nab-or G2-sensitised RBCs did not elicit any response from monocytes here and previously [1] . There was no increase in P-selectin upon Ab binding so the monocyte responses to B2 G1 nab, G1 nac and G2 Abs were not artefacts caused by platelet activation. However, the CL response to B2 G1 showed different kinetics to the responses to the other B2 Abs. The slow CL responses to P-G1 nab, P-G1 nac or P-G2 may have been due to platelets first adhering to monocytes through P-selectin and then causing activation through low-affinity interactions with FcγR. The fast response to P-G1 reflected the strong binding of IgG1 to FcγRI that negated the need for prior P-selectin interactions except at low Ab density. This fits with the observations that unsensitised platelets can adhere to monocytes and that the CL response upon subsequent addition of Ab is faster and greater than when sensitised platelets are added to monocytes [11] . This pre-adhesion enhancement operated for all four B2 variants. The association of platelets with monocytes appears to be the slowest event in the monocyte activation. Following pre-adhesion, the close proximity of the platelet Ag and monocyte FcγR presumably allows higher avidity Ab binding and offsets the time taken for the Abs to diffuse to the binding sites.
The binding profiles of B2 G1 nab and G1 nac were reflected in the pattern of FcγR utilisation in the monocyte activation experiments. Despite the low activity exhibited by the mutant IgGs, the FcγRI and FcγRII blocking agents each eliminated CL due to one mutant but not the other, which indicated that specific FcγR-mediated events were being inhibited. Importantly, blocking FcγRIIa abolished the response due to G2 and G1 nab, which supports our suggestion that it is the interactions of G1 nab with FcγRII that are biologically relevant. Blocking FcγRI inhibited G1 and G1 nac activity although, as previously [11] , the response to G1 could not be eliminated entirely. Presumably, this is because the Ab could act through FcγRII in the presence of P-selectin tethering. Conversely, blocking FcγRII did not reduce the response due to G1 and G1 nac and tended to enhance responses to P-G1, as was previously reported for RBCs and platelets sensitised with IgG1 [11] . The selectivity of IV.3 for FcγRIIa over FcγRIIb means the enhancement was not caused by blockade of the inhibitory receptor but perhaps by forcing G1 to interact with FcγRI rather than, less productively, with FcγRIIa.
We have shown that Fog-1 G1 nab-sensitised RBCs can adhere to macrophages without this resulting in phagocytosis and that the major interactions of G1 nab Ab are with FcγRII. In vivo, the interactions used by macrophages to survey RBCs for signs of aging [14] , possibly enhanced by ex vivo alterations to the RBCs, might augment the modest Ab binding to FcγRIIa and FcγRIIb. Nevertheless, a large proportion of the Fog-1 G1 nab-coated RBCs retained by splenic macrophages was returned to the circulation rather than undergoing phagocytosis. In contrast, there was no evidence for Ab-mediated splenic retention of platelets sensitised with G1 nab alone. Although levels of circulating P-G1 nab fell before rising to a plateau at 2 h post-injection, this behaviour was observed for unsensitised platelets concurrently and previously [10, 15] . Platelet distribution may have been temporarily affected by partial activation during ex vivo handling, which was substantiated by the small increases in P-selectin levels observed for all platelet types [10] . When labelled platelets were infused as part of autologous platelet transfusions, intravascular levels fell for the first hour whilst activity over the spleen increased [15] . A dynamic equilibrium of labelled platelet distribution between organ pools and circulation was reached after 2 h.
In the platelet survival study, it was the platelets sensitised with B2 G1 nab and G1, rather than G1 nab alone, for which there was evidence of Ab-mediated retention in the spleen. In this case, G1 and P-selectin would be acting to promote association with splenic macrophages, which would allow G1 nab to bind to FcγRII. The balance between the interactions with the activating FcγR and the inhibitory FcγRIIb would then determine the fate of the captured platelets. It appears that the alteration in bias of the G1 nab constant region away from activatory receptor binding is sufficient to prevent destruction of these platelets.
We have seen other demonstrations of tethering through a high avidity interaction (as through P-selectin) giving significance to low-affinity interactions that are not themselves strong enough to promote cell-to-cell interactions. When testing the ability of Fog-1 IgGs to inhibit G1-mediated monocyte CL, we saw that G2 was not as efficient an inhibitor as some mutant IgGs despite the inability of G2-coated RBCs to stimulate CL activity [1] . The reduced capacity of G2 to inhibit was eliminated by blockade of FcγRII (AGH unpublished data). Similarly, an IgG2 Ab was less effective than a mutant IgG2 in inhibiting the capture of neutrophils by IgG1 even though IgG2 was unable capture neutrophils when used alone [16] . The potential for low-affinity interactions to amplify the effects of higher affinity interactions has implications for the roles of IgG2 and IgG4 in vivo and, in particular, hinders the use of these subclasses as 'inert' constant regions for therapeutic blocking Abs. The shift in activation/inhibition bias exhibited by G1 nab, coupled with its lower FcγR binding overall, means it should be considered as an alternative to IgG2 or IgG4 when selecting a constant region for blocking Abs.
Materials and methods
Ab production
Production and characterisation of recombinant IgG1 and mutant G1 ab forms of Fog-1 have been described [1, 3, 4] . Fog-1 G1 nab was produced by removing the G1m(1,17) allotypic residues from G1 ab, without effect on its properties [5] .
Generation of B2 G1, a human IgG1,λ version of an anti-HPA-1a single-chain Fv, and B2 G1 nab have been described [8, 9] . B2 IgG2 and G1 nac heavy chain vectors were constructed by exchange of restriction fragments between existing vectors [1, 8, 9] and were each cotransfected with the B2 λ-chain expression vector [8] to produce B2 G2 and B2 G1 nac Abs.
Platelet survival study: Analysis of plasma-associated radioactivity
The determination of the in vivo survival of platelets, which were unsensitised or sensitised with B2 G1, B2 G1 nab or a mixture of these two Abs, has been described [10] . Local Ethical Committee approval and informed consent of all subjects were obtained. For each volunteer, two samples of autologous platelets received a different sensitisation and were radiolabelled with 51 Cr or 111 In before re-infusion. Adjusted counts for the cellular fractions of samples taken post-injection were used to generate platelet survival curves. Here, the data for the radioactivity associated with the plasma have been analysed. This is only informative for platelets labelled with 111 In since 51 Cr shows a high elution rate.
Adjusted 111 In counts for the plasma fractions were expressed as a percentage of the injected dose and combined for volunteers receiving the same Ab combinations.
Cell lines bearing human FcγR
Cell lines transfected with cDNA expression vector constructs to express single human FcγR have been variously obtained.
For FcγRI, the cell line was B2KA (S. Gorman and G. Hale, unpublished) and CHO cells expressing FcγRIIIb of allotypes NA1 and NA2 [17] were kindly provided by J. Bux. FcγRIIIa of allotypes 158F and 158V were expressed as GPI-anchored receptors in CHO [18] . FcγRIIa of allotypes 131R and 131H and FcγRIIb were expressed in CHO cells as transmembrane proteins. Briefly, cDNA was synthesised from human PBMC RNA using specific primers and amplified by nested PCR to yield HindIII -XbaI DNAs, which comprised the whole receptor coding region including signal sequence and cytoplasmic domain. cDNAs encoding FcγRIIa 131H and FcγRIIb were obtained by mutation of the highly homologous FcγRIIa 131R and FcγRIIc DNAs, respectively. cDNAs were inserted into pcDNA3.1/Hygro(+) (Invitrogen, Paisley, UK), transfected into CHO cells and receptor-expressing clones isolated as described [18] .
Measurement of binding to FcγR transfectants
Binding of monomeric IgG to B2KA cells expressing FcγRI was measured as previously described [1] except that, for the B2 Abs, 80 μg/mL biotin-conjugated goat anti-human λ-chain Abs (Sigma, Poole, UK) were used as the first detection reagent.
Binding to FcγRII and III receptors was measured by precomplexing the Abs with equimolar amounts of F(ab') 2 fragments, which recognised the light chain [4] : goat F(ab') 2 anti-human κ (Rockland) for Fog-1 and goat anti-human λ-chain F(ab') 2 molecules (AbD Serotec or Rockland) for B2 Abs. Human IgA1,κ purified myeloma protein (The Binding Site, Birmingham, UK) or IgA,λ (Jackson ImmunoResearch, Newmarket, UK) were used as negative control test Abs. Complexes were detected using FITC-conjugated F(ab') 2 fragments of rabbit anti-goat IgG, F(ab') 2 -specific Abs (Jackson ImmunoResearch) or FITCconjugated donkey anti-goat IgG Abs (AbD Serotec).
Levels of fluorescence were determined using a CyAn ADP flow cytometer and Summit v4.3 software (DakoCytomation, Ely, UK) or on a FACScan flow cytometer and LysisII software (Becton Dickinson, Oxford, UK).
ADCC
Cryopreserved R 1 R 2 RBCs (50 μL packed cells) were thawed, washed and treated with papain at 37
• C for 5 min. They were washed once in PBS, labelled with 51 Cr at 37 • C for 2 h, washed twice and resuspended at 4 × 10 5 cells/mL in RPMI + 10%
FCS. PBMC were isolated by density gradient centrifugation from EDTA-anti-coagulated blood pooled from six normal donors. Cells were washed three times using RPMI containing heparin before adherent cells were removed by incubation in tissue culture flasks at 37
• C for 1.5 h in a humidified atmosphere of 5% CO 2 in air.
Non-adherent cells were resuspended in RPMI + 10% human AB serum at 6 × 10 6 cells/mL.
Fifty microlitres volumes each of Fog-1 Ab dilutions in RPMI, non-adherent mononuclear cells and RBCs were added sequentially to wells of a U-bottomed plate. The plate was centrifuged at 75 × g for 3 min and incubated at 37
• C overnight in a humidified atmosphere of 5% CO 2 in air. Samples of 100 μl of the supernatants were counted in a γ-counter. Lysis was expressed as a percentage of the lysis achieved with 1% Triton X-100 after subtraction of spontaneous lysis observed in the absence of test Ab.
CL assay of monocyte activation by sensitised RBCs
Cryopreserved R 1 R 2 RBCs were thawed, washed and resuspended in PBS + 0.5% w/v human albumin at 2 × 10 8 cells/mL. Forty microlitres samples of cells were added to 100 μL volumes of serially diluted Fog-1 Ab in V-bottom well plates and incubated at 37
• C for 60 min. The sensitised RBCs were washed three times and resuspended in 200 μL HBSS. PBMC were isolated by density gradient centrifugation from EDTA-anti-coagulated blood pooled from six normal donors. Cells were washed using PBS + 0.5% human albumin and resuspended in HBSS containing 25% RPMI and 2.5% FCS. Samples of 100 μl were dispensed into wells of a flat-bottomed white opaque 96-well plate and incubated at 37
• C for 2 h in a humidified atmosphere of 5% CO 2 in air. The plates were then placed in a luminometer (Anthos Lucy 1, Labtech International, Ringmer, UK). Hundred microlitres pre-warmed luminol (Sigma) and 20 μL sensitised RBCs were added to each well. The CL response was monitored at 37
• C for 60 min, integrated and expressed in Relative Light Units as the mean of the response from duplicate wells.
Macrophage adhesion and phagocytosis
Mononuclear cells were isolated from individual donors by density gradient centrifugation and added to a six-well plate at 2 × 10 7 cells/well. The plate was incubated at 37 
CL assay of monocyte activation by sensitised platelets
Platelets were obtained from apheresis platelet donors of known HPA-1 genotype [19] . To minimise platelet activation, one part platelet-rich plasma isolated from citrated whole blood was diluted sixfold in modified Tyrode's solution with 10% acid citrate dextrose (2.5% w/v tri-sodium citrate, 1.37% w/v citric acid, 2% w/v glucose) and 0.5% BSA. Platelets were centrifuged at 700 × g for 10 min, washed three times and resuspended in the same solution at 3 × 10 8 /mL. The preparation was discarded if there were any signs of platelet clumping. Samples of 66 μL platelet suspension were incubated with anti-HPA-1a Ab or, as negative control, human IgG1 varicella zoster virus Ab (VAZO-5, International Blood Group Reference Laboratory, Bristol, UK) in a U-bottomed 96-well microplate for 30 min at 37
• C. Platelets were washed four times and re-suspended in 200 μL HBSS containing 0.5% BSA. Determination of plateletbound IgG and P-selectin expression was achieved by incubation with RPE-conjugated goat anti-human IgG (Jackson ImmunoResearch Laboratories) or CD62P Abs (AK-6, Serotec). Washed platelets were analysed by flow cytometry (EPICS XL-MCL, Coulter Electronics, Luton, UK). Platelets were identified by particle size using a previously defined region that includes >95% of CD41-positive events and the mean fluorescent intensity of 10 000 events was recorded. Monocytes were prepared from whole blood as previously described [11] . The blood was either pooled from six random donors or from donors typed for the FcγRIIa 131R/H polymorphism. Fifty microlitres sensitised platelet suspension and 50 μL of pre-warmed 4 mM luminol were added to wells containing monocytes in 100 μL HBSS/2% FCS. CL was recorded at 37
• C using an Anthos Lucy1 (Labtech International), taking 1 s measurements every 2.35 min for 47 min. The CL response was calculated as the sum of the first seven readings, with each sample tested in duplicate [11] . Statistical analysis was performed using the Student's t-test for significant differences between treatments. When examining platelet-monocyte adhesion, monocytes were isolated from donors homozygous for HPA-1b; 5 × 10 6 HPA-1a/1b platelets were added in 50 μL HBSS/BSA, and platelets and monocytes were incubated together for 30 min prior to addition of HPA-1a Ab and measurement of CL responses as before.
To assess the effect of blocking FcγRI on CL responses, monocytes were incubated for 20 min with 20 μg/mL monomeric murine IgG2a (BRIC163, IBGRL, Bristol, UK). Alternatively, FcγRII was blocked with Fab fragments of mAb IV.3 at 20 μg/mL (Medarex, Minnesota) and monocytes from donors homozygous for the FcγRIIa 131R allotype were used so that blockade of receptor could be confirmed by inhibition of the CL response to a murine IgG 1 Ab. The CL assay continued with addition of sensitised platelets.
